Bank Hapoalim BM’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.09M | Sell |
2,276
-253
| -10% | -$256K | 0.32% | 45 |
|
|
2025
Q4 | $2.72M | Sell |
2,529
-172
| -6% | -$164K | 0.24% | 49 |
|
|
2025
Q3 | $2.06M | Sell |
2,701
-370
| -12% | -$275K | 0.25% | 56 |
|
|
2025
Q2 | $2.39M | Sell |
3,071
-143
| -4% | -$111K | 0.33% | 52 |
|
|
2025
Q1 | $2.65M | Sell |
3,214
-116
| -3% | -$96.5K | 0.38% | 47 |
|
|
2024
Q4 | $2.57M | Sell |
3,330
-2,035
| -38% | -$1.68M | 0.42% | 49 |
|
|
2024
Q3 | $4.75M | Sell |
5,365
-169
| -3% | -$152K | 0.72% | 39 |
|
|
2024
Q2 | $5.01M | Sell |
5,534
-548
| -9% | -$438K | 0.71% | 41 |
|
|
2024
Q1 | $4.73M | Buy |
6,082
+871
| +17% | +$620K | 0.61% | 43 |
|
|
2023
Q4 | $3.04M | Sell |
5,211
-1,366
| -21% | -$797K | 0.42% | 55 |
|
|
2023
Q3 | $3.53M | Sell |
6,577
-1,232
| -16% | -$635K | 0.57% | 44 |
|
|
2023
Q2 | $3.66M | Sell |
7,809
-1,245
| -14% | -$522K | 0.52% | 49 |
|
|
2023
Q1 | $3.11M | Sell |
9,054
-2,753
| -23% | -$928K | 0.43% | 57 |
|
|
2022
Q4 | $4.32M | Sell |
11,807
-805
| -6% | -$285K | 0.54% | 49 |
|
|
2022
Q3 | $4.08M | Sell |
12,612
-400
| -3% | -$127K | 0.51% | 53 |
|
|
2022
Q2 | $4.22M | Buy |
13,012
+4,164
| +47% | +$1.25M | 0.53% | 52 |
|
|
2022
Q1 | $2.53M | Sell |
8,848
-1,200
| -12% | -$309K | 0.26% | 79 |
|
|
2021
Q4 | $2.77M | Sell |
10,048
-32
| -0.3% | -$8.11K | 0.28% | 71 |
|
|
2021
Q3 | $2.33M | Buy |
10,080
+106
| +1% | +$26.2K | 0.24% | 81 |
|
|
2021
Q2 | $2.29M | Buy |
9,974
+587
| +6% | +$118K | 0.26% | 78 |
|
|
2021
Q1 | $1.75M | Sell |
9,387
-1,557
| -14% | -$305K | 0.22% | 88 |
|
|
2020
Q4 | $1.85M | Sell |
10,944
-19
| -0.2% | -$2.84K | 0.26% | 71 |
|
|
2020
Q3 | $1.62K | Sell |
10,963
-200
| -2% | -$31K | 0.08% | 61 |
|
|
2020
Q2 | $1.83M | Sell |
11,163
-973
| -8% | -$149K | 0.43% | 54 |
|
|
2020
Q1 | $1.68M | Buy |
12,136
+60
| +0.5% | +$8.24K | 0.53% | 42 |
|
|
2019
Q4 | $1.59M | Buy |
12,076
+93
| +0.8% | +$10.8K | 0.35% | 56 |
|
|
2019
Q3 | $1.35M | Buy |
11,983
+2,098
| +21% | +$234K | 0.33% | 57 |
|
|
2019
Q2 | $1.09M | Hold |
9,885
| – | – | 0.27% | 66 |
|
|
2019
Q1 | $1.28M | Buy |
9,885
+700
| +8% | +$85.1K | 0.31% | 59 |
|
|
2018
Q4 | $1.06M | Hold |
9,185
| – | – | 0.34% | 61 |
|
|
2018
Q3 | $986K | Hold |
9,185
| – | – | 0.24% | 78 |
|
|
2018
Q2 | $784K | Sell |
9,185
-150
| -2% | -$12.3K | 0.21% | 86 |
|
|
2018
Q1 | $722K | Buy |
9,335
+2,000
| +27% | +$161K | 0.19% | 97 |
|
|
2017
Q4 | $620 | Hold |
7,335
| – | – | 0.14% | 116 |
|
|
2017
Q3 | $627K | Buy |
7,335
+3,080
| +72% | +$253K | 0.14% | 122 |
|
|
2017
Q2 | $350K | Sell |
4,255
-615
| -13% | -$50.2K | 0.08% | 154 |
|
|
2017
Q1 | $410K | Buy |
4,870
+2,000
| +70% | +$160K | 0.1% | 138 |
|
|
2016
Q4 | $211K | Buy |
+2,870
| New | +$214K | 0.06% | 163 |
|
Other funds holding LLY
VCM
VPM
Bank Hapoalim BM's LLY Position: Q1 2026 in Review
Bank Hapoalim BM reduced its Eli Lilly (LLY) stake by 10% in Q1 2026, selling an estimated $256K and leaving 2,276 shares worth $2.09M. The position accounts for 0.32% of the portfolio, ranked #45.
Bank Hapoalim BM first reported a position in LLY in Q4 2016 and has held it in 38 quarters since. The position peaked at $5.01M in Q2 2024. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Bank Hapoalim BM held 2,276 shares of Eli Lilly worth $2.09M as of Q1 2026.
- Bank Hapoalim BM sold 253 Eli Lilly shares in Q1 2026, an estimated $256K.
- Eli Lilly made up 0.32% of Bank Hapoalim BM's portfolio in Q1 2026, its #45 holding.
- Bank Hapoalim BM first reported a position in Eli Lilly in Q4 2016 and has held it in 38 quarters since.
- Bank Hapoalim BM's Eli Lilly position peaked at $5.01M in Q2 2024.
- 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Bank Hapoalim BM's 13F filing for Q1 2026, filed 4 May 2026.